Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 2c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.23 million versus the consensus estimate of $7.07 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• ZenaTech raises Plurilock Security stake to 12% with new share purchase
• Lockheed Martin wins $83 million Army missile contract